Gedeon Richter to acquire Mayne Pharma in AUD 604 million cash deal
Hungarian drugmaker signs a scheme implementation deed to buy ASX-listed Mayne Pharma at AUD 6.40 a share, gaining a US women's health and dermatology portfolio.
Gedeon Richter has signed a Scheme Implementation Deed to acquire all of Mayne Pharma (ASX:MYX), the companies said on 16 November 2026. The price is AUD 6.40 per share in cash, valuing the target at about AUD 604 million and representing a premium of roughly 99% to Mayne's previous closing price.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release: Gedeon Richter ↗
Article written by VigiEye from the official source (Gedeon Richter). Claims are the company's own. AI-assisted; check the source before acting.